Table 2.
Univariate and multivariate analyses of predictors of Day 100 non-relapse mortality in the study cohort
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR | p | HR 95%CI | p | |
| FO, grade | ||||
| <2 | Reference | Reference | ||
| ≥2 | 15 | <0.001 | 13 3.4–50 | <0.001 |
| Age, years | ||||
| ≤55 | Reference | |||
| >55 | 4.5 | 0.008 | NS | |
| Diagnosis | ||||
| AML/MDS | Reference | |||
| ALL | 1.1 | 0.9 | ||
| CML/MPD | 1.3 | 0.7 | ||
| NHL/HD/MM/CLL | 0.5 | 0.5 | ||
| Disease status at AHCT | ||||
| CR1/CR2 | Reference | |||
| Not CR1/CR2 | 1.2 | 0.8 | ||
| Conditioning regimen | ||||
| Thiotepa | Reference | |||
| TBI | 1.1 | 0.9 | ||
| Other | 1.3 | 0.6 | ||
| HCT comorbidity index | ||||
| ≤2 | Reference | |||
| >2 | 3.1 | 0.04 | NS | |
| Baseline creatinine, mg/dL | ||||
| ≤1 | Reference | Reference | ||
| >1 | 4.7 | 0.005 | 3.5 | 0.03 |
| Baseline weight, kg | ||||
| ≤80 | Reference | |||
| >80 | 0.8 | 0.65 | ||
| Baseline DLCO | ||||
| ≤70 | Reference | |||
| >70 | 0.85 | 0.8 | ||
HR, hazard ratio; FO, fluid overload; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; CML, chronic myeloid leukemia; MPD, myeloproliferative disease; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; AHCT, allogeneic hematopoietic cell transplant; CR1, first complete remission; CR2, second complete remission; TBI, total body irradiation; DLCO, diffusing capacity of the lungs for carbon dioxide.